California Assembly Committee Gives Green Light to Psychedelics Legalization Bill, Signaling Progress in Reform Efforts
In a significant stride toward drug policy reform, a bill to legalize the possession and facilitated use of certain psychedelics in California has received approval from a second Assembly committee. The legislation, spearheaded by Senator Scott Wiener, has successfully cleared the Assembly Health Committee with a resounding 9-2 vote. This latest development brings the bill one step closer to reaching the Assembly floor, garnering attention and support for the keyphrase “psychedelics legalization bill.”
Advocates and supporters of the bill were met with enthusiasm as Senator Wiener expressed his belief in the significant benefits these substances can offer individuals facing mental health and addiction challenges. In his address to the panel members prior to the vote, he emphasized the promising resurgence of research on psychedelics, which had been stifled since the 1960s due to the war on drugs. The potential therapeutic applications of psychedelics have reignited interest, making the bill’s progress an exciting prospect.
This positive outcome is especially noteworthy as the bill faced uncertainties during its referral to the Health Committee, making the approval from this committee a welcome development for supporters. To address concerns raised during the legislative process, the bill was amended by the prior committee, leading to a delay in implementing the legalization of facilitated communal use. Instead, a framework for therapeutic use, including community-based healing, risk reduction, and related services, must be developed and adopted before the facilitation aspect can be legalized.
Another notable addition to the bill emerged during the Assembly Health Committee’s evaluation. A new amendment was introduced, mandating the California Health and Human Services Agency (CHHSA) to establish a workgroup dedicated to studying and making recommendations for a regulatory framework concerning the therapeutic use of psychedelics in facilitated settings. The workgroup is expected to submit its report with findings and recommendations by January 1, 2025, offering a path forward for responsible and informed psychedelic legislation.
The current bill represents a more refined version of Senator Wiener’s previous attempt at legalization, addressing concerns and limitations raised during the prior session. This time, the legislation focuses on legalizing the possession, preparation, obtaining, transfer, and transportation of specific amounts of psilocybin, psilocyn, DMT, ibogaine, and mescaline for personal or facilitated use. It is worth noting that synthetic psychedelics such as LSD and MDMA are excluded from the scope of the bill, setting it apart from the previous iteration.
Apart from enabling personal possession, the bill specifically caters to community-based healing involving these entheogenic substances. Previous references to group counseling were removed through an author’s amendment, emphasizing technical changes to refine the legislation further. Furthermore, the bill seeks to repeal the state ban on drug paraphernalia related to the covered substances, thus eliminating unnecessary barriers to their responsible use.
Two significant changes differentiate this current bill from its predecessor. Firstly, synthetic psychedelics like LSD and MDMA are no longer part of the substances eligible for legalization, with the legislation focusing solely on those derived from plants or fungi. This adjustment aimed to shift law enforcement organizations from opposing the bill to adopting a neutral stance, ultimately fostering a more favorable environment for its passage. Additionally, peyote, a cactus traditionally used in ceremonial practices, is excluded from the list of legalized substances, addressing concerns raised by advocates and indigenous groups regarding its sustainability.
Unlike the previous version, this bill no longer includes a provision mandating a study to explore future reforms. Senator Wiener deemed this study unnecessary due to the extensive research already conducted and ongoing in the field of psychedelics. With the current body of evidence and growing momentum for reform, the bill prioritizes practical implementation over further study.
The bill also outlines the allowable amounts of various psychedelics for personal possession. These limits include 2 grams of DMT, 15 grams of ibogaine, 2 grams of psilocybin, or up to 4 ounces of a plant or fungi containing psilocybin, and 2 grams of psilocyn, or up to 4 ounces of a plant or fungi containing psilocyn. These quantities offer clear guidelines to ensure responsible and safe usage of these substances.
As the bill continues its journey through the legislative process, the question of Governor Gavin Newsom’s support arises. However, the governor has remained neutral, neither expressing support nor opposition to the legislation. Nevertheless, advocates remain hopeful that the bill’s progress, combined with the increasing national momentum for psychedelics reform, will pave the way for its enactment.
The drive for psychedelics reform extends beyond California’s borders, with other states actively pursuing similar initiatives. For instance, a bill in Nevada aims to establish a working group to study psychedelics and develop a plan for regulated access to therapeutic use. In Minnesota, a comprehensive bill has been signed, creating a psychedelics task force to prepare for potential legalization. Colorado has already enacted a regulatory framework for legal psychedelics, while North Carolina and Washington State have taken steps to support research and access to psychedelic therapy.
In California itself, progress continues on other fronts. The Assembly committee recently approved a bill to legalize marijuana cafes, and state regulators have allocated funds to support local cannabis business licensing programs. Efforts are also underway to expand California’s marijuana market beyond state borders, seeking guidance on interstate marijuana commerce and potential agreements with other legal states.
As the psychedelic reform movement gains traction nationwide, stakeholders eagerly await the next steps for Senator Wiener’s psychedelics legalization bill. Its progress in the Assembly brings hope for responsible, regulated access to these substances, marking a transformative moment in drug policy reform.
